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Abstract
Background: Silicosis is an occupational disease for which no effective treatment is currently known. Systemic
administration of bone marrow-derived mononuclear cells (BMDMCs) has shown to be safe in lung diseases.
However, so far, no studies have analyzed whether bronchoscopic instillation of autologous BMDMCs is a safe
route of administration in patients with silicosis.
Methods: We conducted a prospective, non-randomized, single-center longitudinal study in five patients. Inclusion
criteria were age 18–50 years, chronic and accelerated silicosis, forced expiratory volume in 1 s <60 % and >40 %,
forced vital capacity ≥60 % and arterial oxygen saturation >90 %. The exclusion criteria were smoking, active
tuberculosis, neoplasms, autoimmune disorders, heart, liver or renal diseases, or inability to undergo bronchoscopy.
BMDMCs were administered through bronchoscopy (2 × 107 cells) into both lungs. Physical examination, laboratory
evaluations, quality of life questionnaires, computed tomography of the chest, lung function tests, and perfusion
scans were performed before the start of treatment and up to 360 days after BMDMC therapy. Additionally,
whole-body and planar scans were evaluated 2 and 24 h after instillation.
Results: No adverse events were observed during and after BMDMC administration. Lung function, quality of life
and radiologic features remained stable throughout follow-up. Furthermore, an early increase of perfusion in the
base of both lungs was observed and sustained after BMDMC administration.
Conclusion: Administration of BMDMCs through bronchoscopy appears to be feasible and safe in accelerated and
chronic silicosis. This pilot study provides a basis for prospective randomized trials to assess the efficacy of this
treatment approach.
Clinical trials.gov identifier: NCT01239862 Date of Registration: November 10, 2010
Keywords: Pneumoconiosis, Chronic inflammation, Lung fibrosis, Cell therapy
Background
Silicosis is a pneumoconiosis caused by inhalation of
crystalline silica particles. Deposition of these particles
in the lung tissue leads to a chronic inflammatory
process with formation of silicotic nodules and collagen
deposition [1, 2]. To date, there has been no effective
therapy to minimize the progression of silicosis [3].
Bone marrow derived-mononuclear cells (BMDMCs)
have exhibited beneficial effects for the treatment of
various diseases due to their multipotent effects [4].
They are easily obtained for autologous transplantation
and can be used on the same day of harvesting at a low
cost and without risk of cell rejection (graft-versus-host
disease) [5]. Additionally, a preclinical study from our
group showed that intratracheal instillation of BMDMCs
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improved lung mechanics and reduced fibrosis in murine
silicosis [6–8].
Based on the foregoing, we tested the hypothesis that
intrabronchial instillation through bronchoscopy of au-
tologous BMDMCs in individuals with accelerated and
chronic silicosis would be feasible and safe.
Methods
A prospective, non-randomized, single-center longitudinal
study was conducted to evaluate the feasibility and safety
of intrabronchial instillation of BMDMCs in patients with
accelerated and chronic silicosis. Patients were referred to
the Clementino Fraga Filho University Hospital (HUCFF),
Federal University of Rio de Janeiro (UFRJ), Brazil, from
other institutions. All patients were investigated and
treated according to the Occupational Lung Diseases
Guidelines for Silicosis of the Brazilian Respiratory Society
[9]. The diagnosis of silicosis was established by history of
occupational exposure to silica crystals, presence of re-
spiratory symptoms such as shortness of breath and
cough, and radiologic abnormalities (bilateral nodular
infiltrates with coalescence). The radiographic changes
were read and confirmed by at least two independent radi-
ologists. Informed consent was obtained from each patient
and the study protocol was approved by the Brazilian
National Ethical and Research Committee/CONEP (study
ID number: CONEP5772008) and registered at Clinical-
Trials.gov (identifier: NCT01239862). In addition to intra-
bronchial autologous infusion of BMDMCs, the patients
received standard care according to the institutional
protocol of the Pulmonary Division/HUCFF/UFRJ; how-
ever, no patients were treated with inhaled or systemic
corticosteroids.
Study population
Forty-one patients with silicosis were screened for eligi-
bility. All but one were male. The reasons for exclusion
were normal spirometry (n = 19), spirometry parameters
outside the study range (n = 5), death during screening
(n = 3), loss to follow-up during screening (n = 3), refusal
to sign informed consent (n = 3), active tuberculosis
found at screening (n = 1), patient outside age range
(n = 1), and psychiatric disorder (n = 1). Five males were
included in the study, with a mean age at intervention of
41 years (range 37–45 years). Patients met the following
inclusion criteria: (1) age between 18 and 50 years; (2)
chronic or accelerated silicosis characterized by the pres-
ence of new areas of fibrosis in high-resolution com-
puted tomography of the lungs in the last 2 years; (3)
pulmonary function tests showing moderate to severe
impairment, characterized by forced expiratory volume
in 1 s (FEV1) <60 % predicted and >40 % predicted, and
forced vital capacity (FVC) ≥60 % predicted but with
arterial oxygen saturation >90 % on room air. Patients
were excluded if they met any of the following criteria:
(1) unable to undergo bronchoscopy for instillation of
cellular material, (2) infectious diseases at the time of
the study or 1 month before enrollment, (3) other lung
diseases, including active tuberculosis, (4) current or re-
cent smoker, within 12 months of inclusion, characterized
by tobacco intake >10 pack-years, (5) intra- or extrathor-
acic malignant neoplasms, (6) autoimmune disorders, (7)
acute or unstable heart failure, (8) acute or uncontrolled
coronary insufficiency, (9) primary hematologic disorders,
(10) osteopathy reflecting increased risk for bone marrow
aspiration, (11) primary or secondary coagulopathies,
(12) liver failure, (13) moderate renal failure (creatinine
level >2 mg/dL), (14) dependence on respiratory or circu-
latory support, (15) pregnancy, (16) human immunodefi-
ciency virus seropositivity, and (17) participation in other
clinical trials. The primary endpoint focused on safety and
included death and respiratory (clinical, radiologic and
functional) deterioration.
Bone marrow aspiration, cell separation and
intrabronchial instillation
Bone marrow aspiration and subsequent cell preparation
were accomplished on the same day as the infusion of
intrabronchial autologous BMDMCs, and lasted 2–4 h.
Collection was performed under local anesthesia and
light sedation, through puncture and repeated aspira-
tions at the posterior iliac crest region. A total of 80 mL
of bone marrow aspirate was collected from each pa-
tient, and after removal of bone and fatty residues,
mononuclear cells were isolated by a Ficoll-Paque Plus
(Amersham Biosciences, São Paulo, Brazil) density gradi-
ent, washed three times in saline solution, resuspended
in saline with 5 % human albumin, and filtered through
a 100-μm nylon filter. After washing, counting, and via-
bility testing, the cells were resuspended in 10 ml saline
solution with 5 % autologous serum, and 2 × 107 cells
were labeled with 99mTc, as described in previously
published protocols [10, 11]. In brief, 500 μl of sterile
SnCl2 solution was added to the cell suspension in 0.9 %
NaCl, and the mixture was incubated for 10 min at
room temperature. Then, 45 mCi 99mTc was added and
incubation was continued for 10 min. After centrifugation
(500 × g for 5 min), the supernatant was removed, the cells
were washed again in saline solution, and the pellet was
resuspended in saline solution. All cell preparation and la-
beling procedures were performed in a laminar flow hood.
Bacteriological analyses and cultures were also carried out
to exclude contamination of the material. A sample of the
isolated BMDMCs was characterized by flow-cytometry
analysis of specific surface antigens as previously described
[11]. The viability of labeled cells was assessed by the
trypan blue exclusion test, and was estimated to be greater
than 90 % in all cases. A 50-mL aliquot of the autologous
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BMDMC solution was instilled into each lung and distrib-
uted through the lobes by a fiber optic bronchoscope over
a 30-min period. Following instillation, patients were posi-
tioned in left and right lateral decubitus and Trendelenburg
position to facilitate dispersion of the instilled cells. After
the procedure, patients were monitored for 1 h and sent to
the Nuclear Medicine Department for examinations.
Flow-cytometry analysis
Isolated BMDMCs were characterized by flow-cytometry
analysis of specific surface antigens. Cells were incu-
bated for 20 min at room temperature with primary
antibodies conjugated with fluorescein isothiocyanate
(FITC), phycoerythrin (PE), allophycocyanin (APC),
peridinin-chlorophyll-protein (PercP), and phycoeryth-
rin/cyanine 7 (PE/Cy7). The markers tested included:
pan-leukocyte, CD45 (Immunostep); pan T cell, CD3
(BD Biosciences Pharmingen); cytotoxic T cell, CD8
(BD Biosciences Pharmingen); helper T cell, CD4 (BD
Biosciences Pharmingen); pan B cell, CD19 (BD Biosci-
ences Pharmingen); NK cell, CD56 (BD Biosciences Phar-
mingen); promonocyte, CD64 (Immunotech); monocyte,
CD14 (IQP); hematopoietic progenitor cells, CD117 (BD
Biosciences Pharmingen) and CD34 (BD Biosciences
Pharmingen); mesenchymal cells, CD105 (Immunostep),
CD73 (BD Biosciences Pharmingen), and CD90 (BD Bio-
sciences Pharmingen); neutrophils, CD31 (BD Biosciences
Pharmingen) and CD33 (BD Biosciences Pharmingen);
and anti-HLA-DR (MHC-II, BD Biosciences Pharmingen).
After staining, erythrocytes were lysed with B&D Lysis
Buffer Solution. Data were acquired on a BD FACS
CANTO cytometer (BD Biosciences) and analyzed with
BD Paint-a-Gate software.
Measured variables
Patient demographics, medical history, vital signs, rou-
tine laboratory tests (blood counts, coagulation tests,
biochemical measurements, liver function tests), electro-
cardiogram, the Saint George Respiratory Questionnaire
(SGRQ), the SF-36 Quality of Life Questionnaire, the
Modified Borg Dyspnea Scale and the 6-min walk test
were assessed using standardized clinical report forms
before BMDMC administration (baseline) and at 1, 3, 7,
30, 60, 90, 180, 360 days after the procedure. Lung func-
tion tests, including diffusing capacity of lung for carbon
monoxide (DLCO) and arterial blood gases, lung CT
scans, and lung perfusion scintigraphy were performed
at baseline, up to 7 days, and 30, 60, 90, 180 and 360 days
after cell transplantation.
Instillation procedure and imaging analysis
After bone marrow harvesting, approximately 2 × 107
BMDMCs were labeled with technetium-99 m (99mTc) and
instilled in the bronchi through fiber optic bronchoscopy.
Whole-body, planar and tomographic scintigraphy was
carried out at 2 h and 24 h after cell transplantation. All
cell preparation and labeling procedures were performed
in a laminar flow. Briefly, 500 μL of sterile SnCl2 solution
was added to the cells and the mixture was incubated at
room temperature for 10 min; 45 mCi of 99mTc was then
added and incubation continued for another 10 min. After
centrifugation (500 × g for 5 min), the supernatant was
removed and the cells were washed in saline solution. The
pellet was also resuspended in saline solution. Viability of
the labeled cells was assessed by the Trypan Blue exclu-
sion test, and was estimated to be greater than 93 % in all
cases. Labeling efficiency (%) was calculated by the activity
in the pellet divided by the sum of the radioactivity in the
pellet plus supernatant and was estimated to be greater
than 90 % in all cases. Perfusion scintigraphy with 99mTc-
MAA (Tc-99 m macroaggregated albumin) was performed
before and 30, 60, 120, 180 and 360 days after BMDMC
therapy. For regional analysis in both the anterior (A) and
posterior (P) images, rectangular regions of interest, equal
in size, were drawn over the whole lung (A-whole lung
and P-whole lung). Both lungs were divided into six
regions of interest: right upper, right middle, right lower,
left upper, left middle, and left lower lung fields. Regional
blood flow evaluated by 99mTc-MAA perfusion scintig-
raphy in each region of interest was calculated as per
Ohno et al. [12]: QPS (%) = [(Aroi + Proi/2)/(Awhole lung +
Pwhole lung 2)] × 100, where QPS is quantitative perfusion
scintigraphy, Aroi is the anterior region of interest, Proi is
the posterior region of interest, Awhole lung is the anterior
whole lung, and Pwhole lung is the posterior whole lung.
Statistical analysis
The Kolmogorov–Smirnov test with Lilliefors’ correction
was used to test for normality of data distribution; the
Levene median test was used to evaluate the homogen-
eity of variances. The time course of functional data was
evaluated using analysis of variance (ANOVA) followed
by Tukey’s test. Differences in quality of life and percent-
age of perfusion over time were assessed by repeated
measures ANOVA on ranks followed by Tukey’s post
hoc test. The single imputation method of regression
substitution for missing data of two patients at one time
point in lung function analysis at 360 days was used.
Nonparametric data were analyzed using repeated mea-
sures ANOVA on ranks followed by Tukey’s post hoc
test. Parametric data are expressed as means ± standard
error of the mean; nonparametric data are expressed as
the median (interquartile range). The SigmaStat 3.1 stat-
istical software package (Jandel Corporation, San Rafael,
CA, USA) was used. A p-value <0.05 was considered
significant.
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Results
Five patients were included in the study and followed up
for 1 year after intrabronchial instillation of autologous
BMDMCs. Table 1 presents the patients’ characteristics
at entry. All were men, had a mean age at intervention
of 41 years (range 37–45 years) and a mean of 10 years
(range 3–13 years) of dyspnea on exertion, and were
nonsmokers or former-smokers. Exposure to silica was
the result of sandblasting (n = 3), quarry truck driving
(n = 1), and stone carving (n = 1). Three had a history of
tuberculosis treatment in the past, with no activity or se-
quelae at the time of the study. Lung function findings
included a mean post-bronchodilator FEV1 of 58.6 %
(range, 48.3–64.1 %) and FVC of 87.9 % (61.9–100.1 %),
denoting airflow obstruction. The main finding on CT
scans was disseminated small nodules and traction bron-
chiectasis. Sequential CT scans were performed until
D360 in all participants, and no major changes were
noted compared to the pre-intervention images.
Bronchoscopy and administration of BMDMCs were
well tolerated. Two patients experienced mild wheezing
after the infusion, which resolved quickly with broncho-
dilator nebulization. No immediate respiratory, cardiovas-
cular, or hematological complications or other adverse
events were observed throughout the 1-year follow-up.
Table 2 describes the progression of respiratory function
during the study. After the first month, FEV1 improved in
the first patient, with no further changes in other patients.
Figure 1 illustrates the progression of quality of life do-
mains during the follow-up period, as measured by the
SF-36 questionnaire. These parameters remained stable
throughout the observation period.
Imaging findings are shown in Figs. 2, 3 and 4. Figure 2a
is a representative image of the heterogeneous distribution
of the labeled cells in both lungs 2 h after instillation, with
some uptake in the mouth and stomach due to swallowing
of the instilled cells during bronchoscopy. Cells were iden-
tified in the lungs 24 h after instillation, with a similar
distribution as at the 2-h time point (Fig. 2b). Figure 3
illustrates that cells were located mainly at sites exhibiting
advanced fibrotic damage in the lungs.
Follow-up lung perfusion findings are illustrated in
Fig. 4. Statistical analysis demonstrated that percent perfu-
sion at the apex of the right and left lungs did not differ
during the study period. In the middle third, percent per-
fusion was increased at day 30 in the right lung, whereas
in the left lung it was higher at day 60 and remained un-
altered at days 120, 180, and 360. In the base of the right
lung, percent perfusion was higher at days 60, 120, 180,
and 360 compared with baseline, whereas a significant
Table 1 Demographic and clinical characteristics of the participants
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age at intervention
(years)
43 37 43 45 37
Sex Male Male Male Male Male
Race White White White White Black





13 5 3 11 10
Main symptom Dyspnea on exertion Progressive
dyspnea








Tuberculosis in 1999 Pneumonia in 2005 Tuberculosis in
2002





Post-BD FEV1 (%) 55.7 48.3 62.1 64.6 62.9
Post-BD FVC (%) 89.3 61.9 94.7 100.1 93.7
Main CT findings
at admission
Irregular opacities, mainly at












Date of infusion 8 Aug 2009 27 Aug 2009 3 Sep 2009 26 Oct 2012 4 Feb 2010
Last outpatient
visit and status
3 Mar 2015, stable 3 Dec 2014, stable 3 Dec 2012, stable 22 Nov 2014, stable 22Aug2011, active
TBa
BD Bronchodilator, FEV1 Forced expiratory volume in 1 s, FCV Forced vital capacity, CT Computed tomography, UULL Upper lobes, TB Tuberculosis
amoved to another state
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difference was observed at days 30 and 180 in the left lung
(Fig. 4).
Discussion
The present study evaluated the safety of autologous
BMDMC administration through bronchoscopy in pa-
tients with silicosis over a period of 360 days. To the best
of our knowledge, this was the first study to evaluate the
safety of autologous BMDMCs in patients with silicosis.
The procedure was well tolerated and no adverse events
were observed in the follow-up period. Even though no
significant changes were reported in lung function and
quality of life, autologous BMDMC transplantation seems
to have led to an early increase in perfusion at the base of
both lungs, which remained increased for the duration of
the follow-up.
Recent studies have investigated the impact of either au-
tologous BMDMCs or mesenchymal stem cells (MSCs) on
lung diseases [13–16]. Both cells present particular advan-
tages: BMDMCs can be used in autologous transplantation
Fig. 1 Evolution of quality of life domains (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-
emotional, mental health), as measured by the SF-36 questionnaire, during the 360 days follow-up period. All parameters remained stable
throughout the observation period. Values are median (25th–75th percentile) of 5 patients at each time point
Table 2 Functional parameters
Day 0 Day 7 Day 30 Day 60 Day 180 Day 360
FVC (%) 88.0 ± 15.1 86.3 ± 15.5 87.0 ± 17.2 86.1 ± 14.1 83.8 ± 14.5 88.0 ± 22.8
FEV1 (%) 58.7 ± 6.7 56.9 ± 5.4 57.9 ± 5.6 57.6 ± 4.8 55.6 ± 6.6 55.5 ± 7.2
TLC (%) 87.1 ± 17.3 87.5 ± 18.0 86.9 ± 23.0 86.3 ± 18.7 87.8 ± 18.4 84.5 ± 20.5
DLCO (%) 60.0 ± 16.4 60.2 ± 16.5 55.8 ± 17.9 58.5 ± 14.3 56.0 ± 17.0 57.5 ± 5.0
Data presented as mean ± standard deviation of 5 silicotic patients
FEV1 Forced expiratory volume in 1 s, FCV Forced vital capacity, TLC Total lung capacity,
TLC Total lung capacity, DLCO Diffusing capacity of the lung for carbon monoxide
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on the same day of harvesting, avoiding common compli-
cations such as graft-versus-host disease, whereas MSCs
have multilineage differentiation potential and immune-
privileged features that enable allogenic use. So far,
clinical studies have demonstrated the safety of sys-
temic BMDMC/MSC infusion in lung diseases, with
no early or late adverse effects reported [13]. Intraven-
ous infusion is often used in preclinical and clinical
studies for the delivery of various cell types, since this
route of administration provides broader biodistribution
and is easy to perform [17]. However, the administration
of BMDMCs through bronchoscopy into different areas of
the lungs may result in a greater number of cells at the site
of injury [18, 19]. We administered a fixed amount of
BMDMCs (2 × 107), independent of body weight, based
on preclinical and clinical studies on different diseases
[10, 11, 20]. To evaluate the early distribution of the
injected cells into the lungs, cells were labelled with
99mTc on the basis of previously published protocols [21,
22]. In vivo imaging and quantification of stem cells is an
essential tool for stem cell tracking, although it has inher-
ent limitations. For instance, regardless of which tech-
nique is used, cell labeling may cause cellular damage
due to the labeling chemicals, and should be carefully
RL LL
A B
Fig. 2 a Representative image of whole-body scintigraphy showing the biodistribution of 99mTc-labeled BMDMCs 2 h after instillation in one
patient; stem cells are seen mainly in the lungs. b There is also uptake in the mouth and stomach, due to minor swallowing during instillation.
RL, right lung; LL, left lung; BMDMCs, bone marrow–derived mononuclear cells; 99mTc-BMDMCs, 99mTc-labeled bone marrow–derived
mononuclear cells
Computed tomography (CT) 
99mTc-BMDSC SPECT
A B C
Fig. 3 Representative image of CT and 99mTc-BMDSC SPECT showing correspondence of a left lung lesion (green triangular area). CT, computed
tomography; 99mTc-BMDSC, 99mTc-labeled bone marrow–derived mononuclear cells; SPECT, single-photon emission computed tomography
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controlled. Due to the short half-life of 99mTc (approxi-
mately 6 h), we cannot rule out that the amount of cells in
the lungs may increase at later time points. Other radio-
pharmaceutical compounds such as indium-111 oxine
would allow monitoring for up to 96 h, but have disadvan-
tages, such as the interval of 18–24 h between infusion
and imaging that is usually necessary, suboptimal photon
energy, and a higher radiation burden for the cells and for
the patient [23]. We also used 99mTc-MAA perfusion
scintigraphy to follow the likely pattern of distribution of
the cells for up to 360 days after infusion.
No adverse events or deaths occurred among the pa-
tients treated with BMDMCs. Clinical, functional and
radiological parameters were evaluated at 1-year follow-up.
The clinical features of this group were stable throughout
the follow-up period and no clinical signs or symptoms of
bronchitis or pneumonia were observed after BMDMC
administration. Even though a 1-year period is not long
enough to allow definitive conclusions, it is well known
that lung function deteriorates more quickly in patients
with silicosis depending on continuation of exposure to
silica dust, age and grade of lung lesions [23–25]. The vol-
unteers in our study were relatively young with moderate
lung lesions, and exhibited clear stabilization of lung func-
tion, which could be attributable to the intervention. This
hypothesis would be more clearly demonstrated if a con-
trol group with similar characteristics was added to the
study. With regard to the quality of life questionnaires,
no changes were seen after 360 days of follow-up. An
early increase in perfusion at the base of both lungs
A
B
RL                LLRL                LL RL                LLRL                LL RL                LL RL                LL
Fig. 4 a 99mTc-macroaggregated albumin perfusion scintigraphy sequences from before cell therapy until 360 days after cell therapy, showing
normal uptake at the right base and decreased uptake at both apexes. Improvement in the left base can be seen from day 120 to day 360.
b Values are median (25th–75th percentile) of 5 patients at each time point. Statistical analysis of lung perfusion, showing significant differences
mainly in the base of the right lungs from day 30 to day 360 as compared with baseline. RL, right lung; LL, left lung
Morales et al. BMC Pulmonary Medicine  (2015) 15:66 Page 7 of 9
was observed and sustained after BMDMC administra-
tion. Based on CT scan analysis, fibrosis was not prom-
inent in the apex of the lung, but distributed across
different lung segments. Therefore, the increased perfu-
sion observed in both lung bases was likely not associ-
ated with a predominance of fibrosis in any specific
segment of the lung. In line with this observation and
based on our preclinical data showing that BMDMCs
reduce fibrosis in a mouse model of silicosis, we may
hypothesize that these cells mitigated progression of
fibrosis through paracrine effects.
Since this is a safety study, analysis was only observa-
tional, and further larger-scale trials are necessary to fully
examine the efficacy of BMDMCs in patients with silicosis.
Experimental studies have demonstrated the efficacy of
systemic and intratracheal administration of BMDMCs in a
murine model of silicosis [6–8, 26] that resembles human
silicosis. BMDMC therapy (intratracheally or intravenously
administered) reduced both lung inflammation and remod-
eling, thus improving lung mechanics, through paracrine
signaling [6–8, 26]. Conversely, in the present study, no
significant changes in lung function or quality of life indica-
tors were observed over 360 days of analysis. The fact that
the clinical result did not reflect the experimental data may
be associated with differences in the course of the disease
between animal models and humans, the number of cells
administered, and the timing of analysis.
Our pilot study was limited by its small sample size;
however, it was the first investigation to evaluate stem-cell
therapy in silicotic patients. Further studies should be per-
formed in a greater number of patients, with the addition
of a control group, and in patients with mild and severe
silicosis. Clinical trials evaluating the effects of MSC ther-
apy in idiopathic lung fibrosis (ILF) have been published
[15, 16]. However, this was the first study that analyzed
the safety of autologous BMDMCs in patients with sili-
cosis and, in contrast with the studies, no adverse events
were observed. In this line, two clinical trials involving the
endobronchial or systemic delivery of autologous adipose
tissue-derived [15] or placenta-derived mesenchymal stem
cells [16] demonstrated that these treatments are not safe
in patients with IPF. In the first clinical trial, transient
fever (50 % of patients), cough, dyspnea, and increased
heart rate (14 % of patients) were observed following each
endobronchial cell administration [15], and one patient
experienced a change in absolute FVC of more than 10 %
at 6 months, suggesting disease progression. A second
phase 1b study on the use of exogenous placenta-derived
MSCs in patients with IPF also observed adverse effects
after therapy [16].
Future perspectives
Clinical studies are required to evaluate the safety of
different doses and treatment intervals of BMDMC
administration and to analyze the efficacy of this approach,
including pulmonary and systemic hemodynamics, lung
function, hospitalizations, infections, and death. The use of
a single infusion or repeated infusions also needs to be ad-
dressed, even though multiple infusions could lead to right
heart overload (and pulmonary hypertension) [27]. Most
patients with silicosis are not diagnosed in the early stages
of the disease, but identification of these patients should be
considered for a clinical trial of cell therapy. Clinical trials
should include patients with different degrees of lung func-
tion impairment due to silicosis.
Conclusion
Based on this preliminary study, the administration of
BMDMCs through bronchoscopy appears to be safe. Cer-
tainly, further clinical investigation of BMDMCs or even
other cell types in patients with silicosis is warranted.
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